Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prograf/Envarsus Conversion Study in Liver Transplant Recipients to Improve Side Effects, Adherence and Quality of Life: a Single-centre Randomized Controlled Trial

NCT05655273 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05655273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05655273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prograf/Envarsus Conversion Study in Liver Transplant Recipients to Improve Side Effects, Adherence and Quality of Life: a Single-centre Randomized Controlled Trial
Lead sponsor
University Health Network, Toronto
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
January 1, 2024
Completion date
February 28, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune system suppression, liver transplant rejection